Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

ViroPharma Shares Rise on Report of Drug Company Interest

Don't Miss Out —
Follow us on:

June 17 (Bloomberg) -- ViroPharma Inc., the maker of a drug for a rare disease, rose the most in five months after a report that drug companies may be interested in buying the company.

The Exton, Pennsylvania-based biotechnology company gained 6.3 percent to $28.87 at the close in New York, the biggest single-day increase since Jan. 15. Reuters reported that ViroPharma is a potential acquisition target, citing unidentified sources familiar with the issue.

ViroPharma sells Cinryze, a drug for hereditary angioedema, a genetic disease that afflicts at least 6,000 people in the U.S. and can cause airway obstruction, according to a description on the company website. Sales of the drug were $327.1 million last year, representing 76 percent of the company’s $427.9 million 2012 revenue, according to data compiled by Bloomberg.

A spokeswoman for ViroPharma didn’t return a call asking for comment on the report.

Robert Langreth in New York at +1-212-617-1886 or rlangreth@bloomberg.net;

To contact the reporter on this story: Robert Langreth in New York at rlangreth@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.